Acute Myeloid Leukemia Therapeutics Market in G8 Countries worth $1.67 Billion by 2020

Published : Dec-2011

The Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 – 2020) analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, and Japan.

Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 – 2020).
Early buyers will receive 10% customization on reports.

Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body from infections caused by bacteria. Acute myeloid leukemia is divided into childhood acute myeloid leukemia and adult acute myeloid leukemia.

Acute myeloid leukemia has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

The acute myeloid leukemia therapeutics market in G8 countries was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD regimen in 2010. AVD regimen accounted for the largest share; i.e. 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cytarabine drug and Quizartinib molecule, with sales amounting to $698 million, $285 million, and $234 million respectively.

According to WHO, acute myeloid leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of acute myeloid leukemia. Global incidence of acute myeloid leukemia was 49,539 in 2008 with the developing countries. Total 62,226 new cases were recorded in 2010 with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.

The U.S. dominates the leukemia drug market in North America with a 90.19% share; whereas Germany dominates the market of Europe with 35.04% share.

The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website

Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
MarketsandMarkets Blog

Filed in: Pharmaceutical, Therapeutics
More Reports
Title Price Buy Now

Asahi Kasei Pharma Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescription drugs are used for the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome and lupus nephritis, and difficulty in urination. Asahi Kasei Pharma offers assay kits that determine glycemic control and detect prediabetes. The company's pipeline includes candidates for acute exacerbation of idiopathic pulmonary fibrosis; chemotherapy-induced peripheral neuropathy; oste......

CTI BioPharma Corp (CTIC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US. CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Al......

Active Biotech AB (ACTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed out. Its key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasquinimod (cancer); Paquinimod (Systemic Sclerosis); and SILC (autoimmune diseases). Its operations are principally focused on the laquinimod projects, which are focused on the treatment of neurodegenerative/inflammatory diseases. Active Biotech has licensing agreements with Teva Pharmaceutical Industries, NeoTX, Ipsen, Teva Neuroscience and MediGene AG. Active Biotech is headquartered in Lun......

Intas Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through i......

Scripps Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Scripps Health (Scripps) is a non-profit healthcare organization, which provides healthcare services including primary care and urgent and emergency care services; preventive services and wellness screening services in San Diego County in the US. Scripps offers specialized medical care with medical departments in most of the major medical and surgical specialties. It operates major acute care facilities in its campuses including Scripps Green Hospital; Scripps Memorial Hospital Encinitas and La Jolla; and Scripps Mercy Hospital. It has a network of integrated facilities, outpatient centers and clinics under Scripps Clinic and Scripps Coastal Medical Center. It also operates Prebys Cardiovascular Institute for heart care. It also offers Scripps Home Health Care services, Scripps H......

Celgene Corp (CELG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of develop......

Jazz Pharmaceuticals Plc (JAZZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz ......

Mylan NV (MYL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company has research and development facilities in the US, Canada, the UK, Ireland, Italy, Germany, India and Japan. Mylan is headquartered in Hatfield, Hertfordshire, the UK......

Koninklijke Philips N.V. (PHIA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical systems, consumer electronics and lighting products. It offers patient care & clinical informatics, imaging systems, healthcare transformation services and home healthcare solutions. The company provides health & wellness, personal care and domestic appliances. Philips offers consumer luminaires, lumileds, professional lighting solutions, light sources & electronics and automotive lighting. The company also focuses on offering green products such as dimming backlights, and image processing inte......

Albany Molecular Research Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclinical, clinical and commercial projects; manufacture of drug product (DP) for new and generic drugs and project management services. The company serves pharmaceutical, agrochemical and other sectors including detergent and cosmetics industries. AMRI offers drug discovery and development services across various therapeutic categories including infectious diseases, neurodegenerative disorders, metabolic disorders, cardiovascular and oncology. It has presence in the US, Europe and Asia. AMRI is head......